Azora Therapeutics, Inc. - 10-Q Filing

Azora Therapeutics reports Q3 2026 results featuring significant equity activity including milestone warrants and subsequent event convertible stock issuances.

SEC EDGAR ·

Tickers: $ADIL

Read the full article at SEC EDGAR

More Regulatory news